Balogh J. Victor D. Asham E.H. et al.

Hepatocellular carcinoma: a review.

J Hepatocell Carcinoma. 3: 41-53Simon T.G. King L.Y. Chong D.Q. et al.

Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies.

Hepatology. 67: 1797-1806El-Serag H.B. Hampel H. Javadi F.

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Clin Gastroenterol Hepatol. 4: 369-380Donadon V. Balbi M. Ghersetti M. et al.

Antidiabetic Therapy and Increased Risk of Hepatocellular Carcinoma in Chronic Liver Disease.

15(20). : 2506-2511Bhat A. Sebastiani G. Bhat M.

Systematic review: preventive and therapeutic applications of metformin in liver disease.

World J Hepatol. 7: 1652-1659Decensi A. Puntoni M. Goodwin P. et al.

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

Cancer Prev Res (Phila). 3: 1451-1461Noto H. Goto A. Tsujimoto T. et al.

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.

PLoS One. 7e33411Wang P. Kang D. Cao W. et al.

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.

Diabetes Metab Res Rev. 28: 109-122Zhang P. Li H. Tan X. et al.

Association of metformin use with cancer incidence and mortality: a meta-analysis.

Cancer Epidemiol. 37: 207-218Colmers I.N. Bowker S.L. Tjosvold L.A.

Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies.

Diabetes Metab. 38: 485-506Gu Y. Wang C. Zheng Y. et al.

Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai.

PLoS One. 8e53411Hsiang J.C. Gane E.J. Bai W.W. et al.

Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients.

J Gastroenterol Hepatol. 30: 591-599Karlstad O. Starup-Linde J. Vestergaard P. et al.

Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.

Curr Drug Saf. 8: 333-348Liu X. Wu H. Zhao L. et al.

Association between insulin therapy and risk of liver cancer among diabetics: a meta-analysis of epidemiological studies.

Eur J Gastroenterol Hepatol. 30: 1-8Singh S. Singh P.P. Singh A.G. et al.

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.

Am J Gastroenterol. 108: 881-891Zhou Y. Zhu G. Liu T. et al.

Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma.

Sci Rep. 6: 33743Bosetti C. Rosato V. Buniato D. et al.

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Oncologist. 18: 148-156Wang F. Zhao S. Zhang M. et al.

Decreased risk of liver cancer with thiazolidinediones therapy in patients with type 2 diabetes: results from a meta-analysis.

Hepatology. 58: 835-836Lee J. Jang S. Nam C.M. et al.

Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study.

Sci Rep. 9: 8532Bosetti C. Franchi M. Nicotra F. et al.

Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.

Pharmacoepidemiol Drug Saf. 24: 771-778Kasmari A.J. Welch A. Liu G. et al.

Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome.

Am J Med. 130 Miele L. Bosetti C. Turati F. et al.

Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk.

Gastroenterol Res Pract. 2015: 570356Zhao Y. Wang Y. Lou H. et al.

Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.

Oncotarget. 8: 81027-81039Stroup D.F. Berlin J.A. Morton S.C. et al.

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group.

JAMA. 283: 2008-2012Wells G.A. Shea B. O'Connell D. et al.

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [online].

()

Meta-analysis in clinical trials.

Control Clin Trials. 7: 177-188

Cochrane Handbook for Systemic Reviews of interventions.

Lin L. Chu H. Murad M.H. et al.

Empirical comparison of publication bias tests in meta-analysis.

J Gen Intern Med. 33: 1260-1267Easterbrook P.J. Berlin J.A. Gopalan R. et al.

Publication bias in clinical research.

Lancet. 337: 867-872Chang C. Lin J. Wu L. et al.

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.

Hepatology. 55: 1462-1472Chang C. Lin J. Wu L. et al.

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus.

J Clin Endocrinol Metab. 97: E1170-E1175Chen H. Shieh J. Chang C. et al.

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.

Gut. 62: 606-615Chiu C. Huang C. Chen Y. et al.

Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.

Intern Med. 52: 939-946Huang M. Chung C. Chang W. et al.

The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan.

Am J Cancer Res. 7: 1606-1616Kao C. Sun L. Chen P. et al.

A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients?.

Ann Oncol. 24: 523-530Lai S. Chen P. Liao K. et al.

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.

Am J Gastroenterol. 107: 46-52Lin C. Huang H. Chu F. et al.

Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study.

PLoS One. 10e0125421Kim G. Jang S. Han E. et al.

Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case-control study.

Int J Cancer. 140: 798-806Hassan M.M. Curley S.A. Li D. et al.

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Cancer. 116: 1938-1946Kawaguchi T. Taniguchi E. Morita Y. et al.

Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.

Liver Int. 30: 479-486Oliveria S.A. Koro C.E. Yood M.U. et al.

Cancer incidence among patients treated with antidiabetic pharmacotherapy.

Diabetes Metab Syndr Clin Res Rev. 2: 47-57Rowley W.R. Bezold C. Arikan Y. et al.

Diabetes 2030: insights from yesterday, today, and future trends.

Popul Health Manag. 20: 6-12Galli A. Mello T. Ceni E. et al.

The potential of antidiabetic thiazolidinediones for anticancer therapy.

Expert Opin Investig Drugs. 15: 1039-1049Galli A. Ceni E. Mello T. et al.

Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.

Hepatology. 52: 493-505Della-Morte D. Palmirotta R. Rehni A.K. et al.

Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Pharmacogenomics. 15: 2063-2082Carulli L. Rondinella S. Lombardini S. et al.

Review article: diabetes, genetics and ethnicity.

Aliment Pharmacol Ther. 22: 16-19Martis S. Peter I. Hulot J. et al.

Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Pharmacogenomics J. 13: 369-377García-Martín E. Martínez C. Ladero J.M. et al.

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Mol Diagn Ther. 10: 29-40Roughead E.E. Chan E.W. Choi N. et al.

Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective Analysis of Large Healthcare Claims Databases in Six Countries.

38(9). : 823-831Boyko E.J. Gerstein H.C. Mohan V. et al.

Effects of ethnicity on diabetes incidence and prevention: results of the diabetes REduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

Diabet Med. 27: 1226-1232Chalasani N. Younossi Z. Lavine J.E. et al.

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.

Hepatology. 67: 328-357Leal I. Romio S.A. Schuemie M. et al.

Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

Br J Clin Pharmacol. 75: 861-868Arnold S.V. Inzucchi S.E. Echouffo-Tcheugui J.B. et al.

Understanding contemporary use of Thiazolidinediones.

Circ Heart Fail. 12e005855Masoudi F.A. Wang Y. Inzucchi S.E. et al.

Metformin and thiazolidinedione use in Medicare patients with heart failure.

JAMA. 290: 81-85

Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk.

Metabolism. 60: 1357-1358Pasello G. Urso L. Conte P. et al.

Effects of sulfonylureas on tumor growth: a review of the literature.

Oncologist. 18: 1118-1125Moore M.A. Park C.B. Tsuda H.

Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.

Eur J Cancer Prev. 7: 89-107Han H. Zhang T. Jin Z. et al.

Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies.

Oncotarget. 8: 50164-50173Singh S. Singh P.P. Singh A.G. et al.

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.

Gastroenterology. 144: 323-332